|Day Low/High||112.97 / 113.40|
|52 Wk Low/High||34.53 / 114.20|
Here are how some of the conference presenters are performing on the market Wednesday
The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 350,261 share increase in total short interest for Spark Therapeutics Inc , to 3,237,358, an increase of 12.13% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.
Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.
Preliminary data as of Dec. 6, 2017, show a 100-percent reduction in annualized bleeding rate (ABR) and 98-percent reduction in annualized infusion rate (AIR) in first four participants
Annualized bleeding rate (ABR) among 10 participants was reduced 97 percent following SPK-9001 administration, while factor IX concentrate use collectively was reduced 99 percent by 1.95 million international units (IU) during the 492-week cumulative follow-up period
Investor teleconference to be held Monday, Dec. 11, at 12:30 p.m.ET
Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing
Spark Therapeutics to receive up to an additional $25 million per terms of amendment
Spark Therapeutics gains gene therapy advisory OK for treatment restoring some sight for patients facing eventual blindness.
Katherine A. High, M.D., will continue to serve as president and head of R&D
Includes exclusive worldwide rights to adeno-associated viral (AAV) gene therapy targeting the liver
Multi-luminance mobility test (MLMT) was the primary endpoint in the Phase 3 trial for investigational LUXTURNA™ (voretigene neparvovec)
Illumina, Spark Therapeutics and Endo International were among the biotech stock movers in premarket trading on Aug. 2.
Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.